This is a StreetInsider.com Premium Only Page

Neovasc (NVCN) – StreetInsider.com Reports

Feb 1, 2023 09:05 AM Neovasc (NVCN) Announces German Reimbursement Renewal

Jan 18, 2023 06:21 AM H.C. Wainwright Downgrades Neovasc (NVCN) to Neutral

Jan 17, 2023 08:09 AM Neovasc (NVCN) to Resume Trading at 8:30 a.m.

Jan 17, 2023 08:01 AM Shockwave Medical (SWAV) Acquires Neovasc (NVCN) for $27.25/sh + $12 CVR

Jan 17, 2023 08:01 AM Shockwave Medical to Acquire Neovasc (NVCN) for Over $27.25 Per Share

Jan 17, 2023 07:55 AM Neovasc (NVCN) Halted, News Pending

Nov 28, 2022 04:48 PM Neovasc (NVCN) Announces Progress on COSIRA-II Clinical Trial

Nov 18, 2022 09:06 AM Neovasc (NVCN) Comments on European Heart Journal Publication

Nov 10, 2022 04:40 PM Neovasc (NVCN) Misses Q3 EPS by 60c

Nov 8, 2022 09:05 AM Neovasc (NVCN) Reducer Obtains U.S. Outpatient Reimbursement

Sep 20, 2022 09:06 AM Neovasc (NVCN) Provides Corporate Update

Jul 26, 2022 09:07 AM Neovasc (NVCN) Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry

Jul 5, 2022 09:05 AM Neovasc (NVCN) Expands Direct Sales Operations to UK

May 16, 2022 09:05 AM Neovasc (NVCN) Regains Nasdaq Compliance

Apr 28, 2022 09:06 AM Neovasc (NVCN) Issues Comments on Publication in European Heart Journal

Mar 24, 2022 09:06 AM Neovasc (NVCN) Consolidates and Extends Convertible Debt

Feb 8, 2022 09:05 AM Neovasc (NVCN) Announces German Reimbursement Renewal and Commercial Progress

Feb 4, 2022 09:07 AM Neovasc (NVCN) Reports Publication of Independent Study Demonstrating Cost Savings when Using Neovasc Reducer

Feb 2, 2022 09:08 AM Neovasc (NVCN) Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Feb 2, 2022 09:06 AM Neovasc (NVCN) Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Jan 20, 2022 09:05 AM Neovasc (NVCN) Announces Publication Supporting the Neovasc Reducer Device

Jan 18, 2022 09:07 AM Neovasc (NVCN) Reports Publication of Case Series of First U.S. Reducer Implants

Nov 30, 2021 09:42 AM Neovasc (NVCN) Announces Neovasc Reducer System Receives National Reimbursement in France

Nov 24, 2021 09:35 AM Neovasc (NVCN) Announces National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System

Oct 21, 2021 09:10 AM Neovasc's (NVCN) Neovasc Reducer Featured in Polish Heart Journal Publication

Sep 28, 2021 09:10 AM Neovasc (NVCN) REDUCER-I Study Published in EuroIntervention Journal

Sep 16, 2021 09:05 AM Neovasc (NVCN) Announces FDA Approval of COSIRA-II Clinical Trial

Aug 17, 2021 09:05 AM Neovasc (NVCN) Announces Submission of COSIRA-II Protocol Supplement to FDA

Jun 18, 2021 09:10 AM Neovasc (NVCN) Says Largest Real-World Registry Supporting Reducer Safety and Efficacy Outcomes Published in International Journal of Cardiology

Jun 10, 2021 03:07 PM Neovasc (NVCN) has implemented a series of strategic initiatives focused on enhancing current shareholder value

Jun 10, 2021 02:58 PM Neovasc (NVCN) Halted, News Pending

Jun 7, 2021 09:11 AM Neovasc (NVCN) Reducer System Receives First National Reimbursement in Europe

Apr 19, 2021 09:12 AM Neovasc (NVCN) Comments on EuroIntervention Article

Apr 16, 2021 09:06 AM Neovasc (NVCN) announced that Tiara Transapical system will be unable to receive European CE mark under current Medical Device Directive regulations

Mar 2, 2021 09:03 AM Neovasc (NVCN) Comments on Clinical Cardiology Journal Publication

Feb 10, 2021 07:35 AM Neovasc (NVCN) Announces $72 Million Registered Direct Offering of Common Shares

Feb 9, 2021 09:00 AM Neovasc (NVCN) Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 5, 2021 09:02 AM Neovasc (NVCN) Comments on Journal of the American Heart Association Publication

Dec 17, 2020 07:10 AM Neovasc (NVCN) Announces Publication of Peer-Reviewed Article in EuroIntervention

Dec 15, 2020 07:03 AM Neovasc (NVCN) Announces First Neovasc Reducer Implants in France

Dec 10, 2020 05:44 PM Neovasc (NVCN) Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Dec 8, 2020 09:05 AM Neovasc (NVCN) Announces $6.1 Million Registered Direct Offering of Common Stock, Warrants

Nov 6, 2020 05:44 AM Neovasc (NVCN) PT Lowered to $2 at SVB Leerink

Oct 28, 2020 07:23 AM Neovasc (NVCN) Announces FDA Advisory Panel Result on Neovasc Reducer Medical Device for the Treatment of Refractory Angina

Aug 13, 2020 09:02 AM Neovasc (NVCN) Provides Corporate Update

Aug 10, 2020 08:08 AM Neovasc (NVCN) Announces US$12.6 Million Registered Direct Offering of Common Stock

Jun 29, 2020 12:01 PM Neovasc (NVCN) Reducer and Tiara Featured at Leading Industry Virtual Conferences

Jun 26, 2020 09:46 AM Neovasc (NVCN) Announces Positive Interim Results from REDUCER-I Study

Jun 25, 2020 09:01 AM Neovasc (NVCN) Regains Compliance with Nasdaq Minimum Market Value Rule

Jun 12, 2020 09:02 AM Neovasc (NVCN) Announces $11.5 Million Registered Direct Offering of Common Shares